Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Utah Medical ProductsUTMD +0.41%73 Return-on-Tangible-Equity is 10.05% as of Jun. 2026, which is 50% below its 10-year median of 20.10. GuruFocus rates UTMD with a GF Score™ of 73/100 and a GF Value™ of $57.89 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 757 Medical Devices & Instruments companies, Utah Medical Products ranks better than 64.07% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Utah Medical Products's annualized net income for the quarter that ended in Jun. 2026 was $10.74 Mil. Utah Medical Products's average shareholder tangible equity for the quarter that ended in Jun. 2026 was $106.91 Mil. Therefore, Utah Medical Products's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 10.05%.
The historical rank and industry rank for Utah Medical Products's Return-on-Tangible-Equity or its related term are showing as below:
UTMD'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 10.04 Med: 20.1 Max: 35.56
Current: 10.04
During the past 13 years, Utah Medical Products's highest Return-on-Tangible-Equity was 35.56%. The lowest was 10.04%. And the median was 20.10%.
UTMD's Return-on-Tangible-Equity is ranked better than 64.07% of 757
companies
in the Medical Devices & Instruments industry
Industry Median: 4.86
vs UTMD: 10.04
Utah Medical Products (NAS:UTMD) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Utah Medical Products Return-on-Tangible-Equity Related Terms
Utah Medical Products Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Utah Medical Products's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Utah Medical Products Return-on-Tangible-Equity Chart
UTMD vs EMBC, SMTI, PDEX: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Utah Medical Products's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Utah Medical Products Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Utah Medical Products's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Utah Medical Products's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 10.05% mean?
Utah Medical Products (UTMD) has a Return-on-Tangible-Equity of 10.05% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Utah Medical Products and its competitors. This is 50% below median its historical median of 20.10. Over the past decade, Utah Medical Products' Return-on-Tangible-Equity has ranged from 10.04 to 35.56. According to the industry distribution chart, Utah Medical Products ranks #272 out of 757 companies in the Medical Devices & Instruments industry, placing it in the top 35.9%.
Is Utah Medical Products' Return-on-Tangible-Equity too high?
Utah Medical Products' current Return-on-Tangible-Equity of 10.05% is 50% below median its 10-year median of 20.10. Over the past 10 years, this metric has ranged from a low of 10.04 to a high of 35.56. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.86. Utah Medical Products' value of 10.05% is 106.8% above this industry median. Based on the distribution chart, Utah Medical Products ranks #272 out of 757 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Utah Medical Products has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Utah Medical Products' Return-on-Tangible-Equity compare to EMBC and SMTI?
According to the Medical Devices & Instruments industry distribution chart, Utah Medical Products ranks #272 out of 757 companies for Return-on-Tangible-Equity. This puts Utah Medical Products in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.86. Utah Medical Products' value of 10.05% is 106.8% above this benchmark. Historically, Utah Medical Products' own Return-on-Tangible-Equity has ranged from 10.04 to 35.56 over the past decade. While the company's 10-year median is 20.10 vs. the industry median of 4.86, Utah Medical Products has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.86, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Utah Medical Products's current Return-on-Tangible-Equity of 10.05% is 106.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Utah Medical Products and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Utah Medical Products's current Return-on-Tangible-Equity is 10.05%, which is 50% below median its own 10-year median of 20.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Utah Medical Products stock overvalued right now?
Based on GuruFocus' analysis, Utah Medical Products (UTMD) is currently considered Modestly Overvalued. The stock's GF Value™ is $57.89, compared to a current price of $70.84 — trading 22.4% above its estimated fair value. The current Return-on-Tangible-Equity is 10.05%, which is 50% below median its 10-year median of 20.10 and 106.8% above the Medical Devices & Instruments industry median of 4.86. Utah Medical Products' overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Utah Medical Products (UTMD), the current Return-on-Tangible-Equity is 10.05% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Utah Medical Products (UTMD) Overvalued in 2026?
Based on GuruFocus' analysis, Utah Medical Products stock appears to be overvalued.
The current stock price of $70.84 is trading 22.4% above its estimated GF Value™ of $57.89.
GuruFocus considers Utah Medical Products to be Modestly Overvalued.
Key valuation signals for UTMD:
Return-on-Tangible-Equity: 10.05% (50% below median its 10-year median of 20.10)
GF Value™: $57.89 vs. price of $70.84 (22.4% above fair value)
Industry Position: 106.8% above the Medical Devices & Instruments median (#272 of 757)
No single metric tells the full story. See the UTMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
73GF Score
Get the complete analysis for UTMD
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UTMD has been successfully added to your 
